EMA will accept biosimilar reference products sourced outside EEA, but not immediately
This article was originally published in SRA
The European Medicines Agency has issued an update to its procedural advice document EMA/940451/2011 that confirms that the agency, with regard to biosimilar applications under the centralised procedure, will accept batches of reference medicinal products sourced from outside the European Economic Area in certain pre-clinical and clinical studies for the comparability exercise1. The change will not happen immediately, however.
You may also be interested in...
Japanese company Daiichi Sankyo has its eye on first-line FLT3-ITD AML indication after rejection of relapsed/refractory plans in EU and US.
Rigel Pharmaceuticals and Jazz Pharmaceuticals are among the companies that could find out this week whether their new drug applications at the European Medicines Agency are likely to be approved for marketing across the EU. The EMA's key scientific committee, the CHMP, will also consider applications from Roche and Novartis.
Novartis is likely to hear this week whether siponomid and osilodrostat will be recommended for marketing across the EU.